[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 126,072,560
  • Shares Outstanding, K 253,805
  • Annual Sales, $ 12,001 M
  • Annual Income, $ 3,953 M
  • EBIT $ 4,681 M
  • EBITDA $ 4,891 M
  • 60-Month Beta 0.30
  • Price/Sales 10.57
  • Price/Cash Flow 28.43
  • Price/Book 6.56

Options Overview Details

View History
  • Implied Volatility 30.08% (+0.07%)
  • Historical Volatility 23.61%
  • IV Percentile 50%
  • IV Rank 33.13%
  • IV High 46.24% on 02/12/26
  • IV Low 22.08% on 08/27/25
  • Expected Move (DTE 9) 15.39 (3.09%)
  • Put/Call Vol Ratio 1.67
  • Today's Volume 1,901
  • Volume Avg (30-Day) 2,124
  • Put/Call OI Ratio 0.80
  • Today's Open Interest 40,187
  • Open Int (30-Day) 47,270
  • Expected Range 482.63 to 513.40

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 34 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $4.25
  • Number of Estimates 6
  • High Estimate $4.47
  • Low Estimate $3.98
  • Prior Year $4.00
  • Growth Rate Est. (year over year) +6.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
420.01 +18.57%
on 06/03/26
503.89 -1.17%
on 06/26/26
+59.61 (+13.60%)
since 06/01/26
3-Month
412.27 +20.80%
on 05/05/26
503.89 -1.17%
on 06/26/26
+50.75 (+11.35%)
since 04/01/26
52-Week
362.50 +37.38%
on 08/11/25
507.92 -1.95%
on 03/10/26
+45.85 (+10.14%)
since 07/01/25

Most Recent Stories

More News
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia

- First and only approved genetic therapy to treat children as young as 2 years for both severe sickle cell disease and transfusion-dependent beta thalassemia - - Approximately...

VRTX : 498.01 (+0.26%)
Therapeutics Stocks Q1 Recap: Benchmarking Vertex Pharmaceuticals (NASDAQ:VRTX)

Therapeutics Stocks Q1 Recap: Benchmarking Vertex Pharmaceuticals (NASDAQ:VRTX)

VRTX : 498.01 (+0.26%)
The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch.

The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout.

IBB : 190.12 (-0.04%)
VRTX : 498.01 (+0.26%)
GILD : 125.97 (-0.29%)
AMGN : 361.33 (-0.22%)
3 of Wall Street’s Favorite Stocks to Consider Right Now

3 of Wall Street’s Favorite Stocks to Consider Right Now

SYK : 313.39 (-0.46%)
VRTX : 498.01 (+0.26%)
CASH : 89.69 (+3.02%)
2 Reasons to Like VRTX (and 1 Not So Much)

2 Reasons to Like VRTX (and 1 Not So Much)

VRTX : 498.01 (+0.26%)
3 Market-Beating Stocks Worth Investigating

3 Market-Beating Stocks Worth Investigating

TPC : 79.51 (-4.17%)
VRTX : 498.01 (+0.26%)
FAST : 47.75 (-0.58%)
Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions

- Data from pivotal studies of CASGEVY in children ages 5–11 with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrate transformative potential in younger patients, consistent...

VRTX : 498.01 (+0.26%)
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference

- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of

VRTX : 498.01 (+0.26%)
Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in the Goldman Sachs 47th Annual Global Healthcare Conference. Dr. Reshma Kewalramani, President and...

VRTX : 498.01 (+0.26%)
Vertex Pharmaceuticals Stock: Is VRTX Underperforming the Healthcare Sector?

Despite Vertex Pharmaceuticals' underperformance relative to the healthcare sector over the past year, Wall Street analysts remain strongly optimistic about the stock’s prospects.

XLV : 159.54 (+0.55%)
VRTX : 498.01 (+0.26%)
REGN : 624.72 (+0.19%)
AMGN : 361.33 (-0.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which...

See More

Key Turning Points

3rd Resistance Point 510.12
2nd Resistance Point 506.42
1st Resistance Point 502.21
Last Price 498.01
1st Support Level 494.30
2nd Support Level 490.60
3rd Support Level 486.39

See More

52-Week High 507.92
Last Price 498.01
Fibonacci 61.8% 452.37
Fibonacci 50% 435.21
Fibonacci 38.2% 418.05
52-Week Low 362.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.